Table 6.
Results for scenario analyses, ICS-tolerant patients
| Scenario | Costs in GBPa | QALYsa | ICER (GBP per QALY gained) | ||
|---|---|---|---|---|---|
|
|
|
|
|||
| LAMA + LABA/ICS | LAMA + LABA/ICS + roflumilast | LAMA + LABA/ICS | LAMA + LABA/ICS + roflumilast | LAMA + LABA/ICS + roflumilast versus LAMA + LABA/ICS | |
| Base case | 22,816 | 23,230 | 5.4839 | 5.5089 | 16,566 |
| A) Baseline number of exacerbations = 1 | 22,464 | 22,881 | 6.2402 | 6.2543 | 29,581 |
| Baseline number of exacerbations = 3 | 23,028 | 23,440 | 4.8638 | 4.8975 | 12,259 |
| B) Incorporation of lung function benefit | 22,816 | 23,170 | 5.4839 | 5.5249 | 8,617 |
| C) Time on first line = 0.5 years | 22,816 | 23,021 | 5.4839 | 5.4967 | 16,068 |
| Time on first line = 2 years | 22,816 | 23,597 | 5.4839 | 5.5309 | 16,628 |
| D) Patients remain on first line | 22,816 | 26,602 | 5.4839 | 5.7111 | 16,661 |
| E) Patients start in very severe COPD | 26,444 | 26,883 | 4.4922 | 4.5279 | 12,310 |
| F) Treatment switch following disease progression | 22,816 | 24,725 | 5.4839 | 5.5834 | 19,186 |
Note:
a
Rounded values.
Abbreviations: GBP, British pound; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; ICS, inhaled corticosteroids; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist.